Ranked by engagement

Top topics — all time page 35

Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.

This week This month This quarter This year All time

1,535 topics · page 35 of 40

Topic	Participants	Replies	Views	Activity
Shoulders, tangent skims, and defensible integration Analytics › HPLC & UHPLC peak integration UV & DAD detection HPLC gradient method Posting this under the heading it deserves: Shoulders, tangent skims, and defensible integration Everything below is what sits behind that. Posting the method first, because I know what the first three…	+16	20	11k	13h
Revisiting: Absolute versus relative contraindications Safety › Contraindications disordered eating pregnancy & planning pancreatitis delayed gastric emptying Revisiting: Absolute versus relative contraindications Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…	+11	15	22k	5mo
Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Compounds › Semaglutide SELECT trial STEP programme effect size randomised trial Second pass at: Why semaglutide's albumin binding is the whole reason weekly dosing works Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet ,…		2	39k	6mo
Comparing documentation quality across the directory, tabulated Sourcing › Vendor reports third-party testing disputed Janoshik Analytical batch & lot numbers Comparing documentation quality across the directory, tabulated — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately…	+7	11	29k	19h
EU-wide position versus national implementation Regional › European Union EMA personal import cost per milligram formulary Solved Under review EU-wide position versus national implementation Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this category…	+22	29	356	11mo
How to read a phase 2 result without treating it as a phase 3 result — what changed since Compounds › Retatrutide TRIUMPH programme randomised trial preprint Solved Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it…	+25	35	568	6mo
Second pass at: Buffers, pH and why a formulation is a formulation Pharmacology › Formulation chemistry counter-ion content cloudy or discoloured solution sterile water Wiki Second pass at: Buffers, pH and why a formulation is a formulation Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I…	+24	28	1.5k	21mo
Follow-up: Glucagon receptor agonism in a weight-loss compound Pharmacology › Receptor biology amylin analogues long read tirzepatide retatrutide Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…	+5	9	21k	7mo
Why this community will not facilitate a group purchase Sourcing › Payments documentation quality payments research use only Asking directly, because I could not find a straight answer: Why this community will not facilitate a group purchase A logistics question, since the answers here are usually better than anywhere else I have…		2	40k	3mo
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Compounds › Repair & healing peptides needs a source preprint BPC-157 Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…	+28	33	1.6k	1mo
[2026 update] Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides BPC-157 observational data TB-500 Solved Publication patterns in the BPC-157 literature, examined Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it…	+15	19	11k	4mo
Reflux appearing for the first time at a dose step Practice › Side effects vomiting fatigue hair shedding constipation Reflux appearing for the first time at a dose step — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have been doing the same thing for…		4	36k	4mo
The nausea timeline across the first four weeks, with a tabulated log — what changed since Practice › Side effects constipation delayed gastric emptying fatigue nausea On the subject in the title: The nausea timeline across the first four weeks, with a tabulated log — what changed since Working notes rather than a conclusion. I have read the maintained page on this and I…	+24	29	2.8k	6mo
Type 2 diabetes and the largest part of the evidence base — does this still hold? Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease PCOS obstructive sleep apnoea Solved Wiki Type 2 diabetes and the largest part of the evidence base — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Asking about a population rather…	+18	25	1.7k	22mo
Follow-up: What this community means by "a source", in practical terms Start Here › Welcome onboarding beginner friendly trust levels guidelines The question in the title: What this community means by "a source", in practical terms I will give what I have already checked below so nobody repeats it. I want to check my reasoning rather than get a…	+16	20	7k	18mo
Osteoarthritis and mechanical versus metabolic improvement Clinical › Comorbidities MASH / hepatic steatosis chronic kidney disease type 2 diabetes obstructive sleep apnoea Osteoarthritis and mechanical versus metabolic improvement Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The…	+2	6	30k	12h
Reporting a good result: why nobody bothers and why they should — one year on Sourcing › Vendor reports batch & lot numbers certificate of analysis documentation quality disputed Wiki Posting this under the heading it deserves: Reporting a good result: why nobody bothers and why they should — one year on Everything below is what sits behind that. Structured report rather than an opinion,…	+19	27	4.7k	18mo
PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? Compounds › Oral incretins orforglipron SOUL trial oral semaglutide PIONEER 6 cardiovascular safety, read as a safety trial rather than an efficacy one — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session…	+23	27	4.8k	22mo
Pricing far outside the range, in either direction Sourcing › Red flags disputed mislabelling underdosing moderation Solved Posting this under the heading it deserves: Pricing far outside the range, in either direction Everything below is what sits behind that. Structured report rather than an opinion, following the format the…	+3	7	27k	7mo
An inter-laboratory comparison on one lot, tabulated — what changed since Analytics › Method validation stability-indicating method LOD & LOQ system suitability precision & repeatability An inter-laboratory comparison on one lot, tabulated — what changed since — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I…	+24	28	3.3k	7mo
Revisiting: US compounding rules and how they changed Regional › North America insurance telehealth compounding On the subject in the title: Revisiting: US compounding rules and how they changed Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…	+5	9	26k	23mo
Particulates in a reconstituted solution: identifying the likely source Analytics › Impurities & related substances counter-ion content data table HPLC water content Posting this under the heading it deserves: Particulates in a reconstituted solution: identifying the likely source Everything below is what sits behind that. Posting the method first, because I know what the…	+15	19	13k	9mo
What a regulator's shortage notice actually authorises Sourcing › Regulatory personal import research use only EMA FDA Solved What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. A logistics question, since the answers here are usually better…	+8	12	15k	17h
Compounds this community declines to help with, and why — does this still hold? Compounds › Other compounds custom synthesis research use only mislabelling Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SCALE ( N Engl J Med ,…	+3	7	26k	7h
Follow-up: How much fluid is actually needed, and how you would know Nutrition & Training › Hydration & electrolytes blood pressure heart rate fatigue How much fluid is actually needed, and how you would know — that is the question, and I have not found it answered plainly anywhere I have looked. Maintenance rather than loss, which is the part of this that…	+17	21	12k	13mo
Retatrutide mass and identity: what a report should show Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with STEP 4 ( JAMA , 2021)…	+22	27	872	22h
Where the integrator drew the baseline, and how much it moved the number Analytics › HPLC & UHPLC system suitability gradient method UV & DAD detection data table Solved Where the integrator drew the baseline, and how much it moved the number — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three…	+20	24	1.6k	8mo
Reading a syringe in poor light, and how to avoid needing to — what changed since Devices › Syringes & needles dead volume subcutaneous injection syringe units needle gauge & length Posting this under the heading it deserves: Reading a syringe in poor light, and how to avoid needing to — what changed since Everything below is what sits behind that. I have read the maintained page on this…	+3	7	27k	27d
Second pass at: Temperature logging at home: what is worth the effort Practice › Storage & stability temperature excursion cloudy or discoloured solution freeze-thaw cold chain Posting this under the heading it deserves: Second pass at: Temperature logging at home: what is worth the effort Everything below is what sits behind that. Reporting something rather than asking about it, in…	+4	8	29k	1mo
Reading a regulatory notice rather than an article about it — what changed since Sourcing › Regulatory research use only MHRA FDA personal import Reading a regulatory notice rather than an article about it — what changed since — setting out what I have, and where I think it stops being reliable. A logistics question, since the answers here are usually…	+28	32	640	13mo